Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Ivax immunotoxin for brain cancer reportedly effective at very low intratumoral doses

Dec. 3, 2001

Biomira suspends two cancer vaccine programs to focus on advanced products

Dec. 3, 2001

Boehringer Ingelheim and ImmunoGen to develop new TAP product

Nov. 30, 2001

Orphan drug status granted for IL-13-PE38 for the treatment of malignant glioma

Nov. 28, 2001

Phase II trial of GVAX cancer vaccine for acute myelogenous leukemia set to commence

Nov. 28, 2001

Cell Genesys and Japan Tobacco modify cancer vaccines agreement

Nov. 27, 2001

Early phase I data for CEA/TRICOM encouraging

Nov. 23, 2001

Virulizin enters phase III for treatment of pancreatic cancer

Nov. 22, 2001

PI-88 may have use in the treatment of leukemia

Nov. 21, 2001

Ethics committee approval granted for PI-88 phase II trial in multiple myeloma

Nov. 14, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...